This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, G. Articles by Chen, W. Y. Search for Related Content PubMed PubMed Citation Articles by Zhang, G. Articles by Chen, W. Y.

A Novel Design of Targeted Endocrine and Cytokine Therapy for Breast Cancer¹

Department of Microbiology and Molecular Medicine, Clemson University, Clemson, South Carolina 29634 [G. Z., W. L., L. H., W. Y. C.], and Oncology Research Institute, Cancer Center, Greenville Hospital System, Greenville, South Carolina 29605 [N. C., W. Y. C.]

The aim of this study is to combine endocrine therapy [human prolactin (hPRL) antagonist, G129R] and immune therapy [interleukin 2 (IL2)] in the design of a fusion protein, G129R-IL2, to treat human breast cancer. This novel approach uses the specific interaction between the G129R and hPRL receptors (PRLRs), thus directly targeting the fusion protein to the malignant breast tissues that have previously been shown to contain high levels of PRLR. The localized bifunctional fusion protein is designed to block signal transduction induced by hPRL as well as to activate T lymphocytes near the tumor site. A bacterial expression system was used to produce G129R-IL2 fusion protein that maintained both G129R and IL2 activities as demonstrated by cell-based assays such as signal transducer(s) and activator(s) of transcription (STAT)5 phosphorylation, breast cancer cell proliferation, and T-cell proliferation. The antitumor activities of G129R-IL2 were demonstrated in vivo using a syngeneic model system with BALB/c mice and EMT6-hPRLR breast cancer cells. After daily injection (i.p.) of G129R-IL2 (100 µg/mouse) for 18 days, the tumor growth in the G129R-IL2-treated group was only one-third the size as compared with that of the control group. The growth rate in the G129R-IL2-treated group is also significantly slower than that of the group treated with G129R alone (200 µg/mouse/day). We hope that this novel bifunctional protein will contribute significantly to human breast cancer therapy.

This article has been cited by other articles:

				A. Chetrit, G. Hirsh-Yechezkel, Y. Ben-David, F. Lubin, E. Friedman, and S. Sadetzki Effect of BRCA1/2 Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian Cancer J. Clin. Oncol., January 1, 2008; 26(1): 20 - 25. [Abstract] [Full Text] [PDF]

				H. A. Risch, J. R. McLaughlin, D. E. C. Cole, B. Rosen, L. Bradley, I. Fan, J. Tang, S. Li, S. Zhang, P. A. Shaw, et al. Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin-Cohort Study in Ontario, Canada J Natl Cancer Inst, December 6, 2006; 98(23): 1694 - 1706. [Abstract] [Full Text] [PDF]

				G. F. Weber, F. C. Gaertner, W. Erl, K.-P. Janssen, B. Blechert, B. Holzmann, H. Weighardt, and M. Essler IL-22-Mediated Tumor Growth Reduction Correlates with Inhibition of ERK1/2 and AKT Phosphorylation and Induction of Cell Cycle Arrest in the G2-M Phase J. Immunol., December 1, 2006; 177(11): 8266 - 8272. [Abstract] [Full Text] [PDF]

				J. F. Langenheim, D. Tan, A. M. Walker, and W. Y. Chen Two Wrongs Can Make a Right: Dimers of Prolactin and Growth Hormone Receptor Antagonists Behave as Agonists Mol. Endocrinol., March 1, 2006; 20(3): 661 - 674. [Abstract] [Full Text] [PDF]

				D. Tan, D. A. Johnson, W. Wu, L. Zeng, Y. H. Chen, W. Y. Chen, B. K. Vonderhaar, and A. M. Walker Unmodified Prolactin (PRL) and S179D PRL-Initiated Bioluminescence Resonance Energy Transfer between Homo- and Hetero-Pairs of Long and Short Human PRL Receptors in Living Human Cells Mol. Endocrinol., May 1, 2005; 19(5): 1291 - 1303. [Abstract] [Full Text] [PDF]